Deltagen s Q1 Revenues Rise on DeltaBase Subscription Revenue | GenomeWeb

NEW YORK, May 3 – Deltagen’s first quarter revenues rose to $2.5 million, compared to $286,000 for the first quarter of 2000.

The company attributed this surge to subscription revenue from its DeltaBase mammalian gene function database. Pfizer and GlaxoSmithkline both subscribed to the database in the latter part of 2000, and Deltagen has additional ongoing agreements with Schering-Plough and Merck.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.